Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease
Stopped The study (NCT03352557) was terminated based on lack of efficacy following the placebo-controlled period readout.
Conditions
Interventions
- DRUG: BIIB092
- DRUG: Placebo
Sponsor
Biogen